Search

Your search keyword '"Accassat S."' showing total 80 results

Search Constraints

Start Over You searched for: Author "Accassat S." Remove constraint Author: "Accassat S."
80 results on '"Accassat S."'

Search Results

1. A prognostic score to identify women at increased risk for abnormal uterine bleeding during anticoagulation for venous thromboembolism

2. COVID-19–associated venous thromboembolism: risk of recurrence and major bleeding

3. Venous thromboembolism characteristics, treatment and outcomes in young adults: findings from the Registro Informatizado de Enfermedad TromboEmbólica registry

4. Towards optimal use of antithrombotic therapy of people with cancer at the end of life: A research protocol for the development and implementation of the SERENITY shared decision support tool

5. Heart Rate and Mortality in Patients With Acute Symptomatic Pulmonary Embolism

9. A prognostic score to identify women at increased risk for abnormal uterine bleeding during anticoagulation for venous thromboembolism

10. Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial

12. Venous thromboembolism characteristics, treatment and outcomes in young adults: findings from the Registro Informatizado de Enfermedad TromboEmbólica registry

13. Towards optimal use of antithrombotic therapy of people with cancer at the end of life:A research protocol for the development and implementation of the SERENITY shared decision support tool

14. Maladie thromboembolique veineuse associée au cancer : combien de patients atteints de cancer du poumon vus en pratique clinique seraient éligibles à un essai contrôlé randomisé sur les AODs ?

15. Predicting the risk of cancer after unprovoked venous thromboembolism: external validation of the RIETE score

16. PO-41: Cancer-associated thrombosis: how many patients seen in clinical practice would be eligible to a randomized controlled trial?

17. Heart Rate and Mortality in Patients With Acute Symptomatic Pulmonary Embolism

19. Venous thromboembolism in patients with autoimmune disorders: a comparison between bleeding complications during anticoagulation and recurrences after its discontinuation

20. The prognostic value of respiratory symptoms and performance status in ambulatory cancer patients and unsuspected pulmonary embolism; analysis of an international, prospective, observational cohort study

21. Liver status and outcomes in patients without previous known liver disease receiving anticoagulant therapy for venous thromboembolism

22. Treatment and long-term clinical outcomes of incidental pulmonary embolism in patients with cancer: An international prospective cohort study

23. Rivaroxaban for stroke prevention after embolic stroke of undetermined source

24. Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial

25. Treatment and long-term clinical outcomes of incidental pulmonary embolism in cancer patients: an international prospective cohort study

28. Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial

29. Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism

32. Heart Rate and Mortality in Patients With Acute Symptomatic Pulmonary Embolism

33. TEMPORARY REMOVAL: PO-41: Cancer-associated thrombosis: how many patients seen in clinical practice would be eligible to a randomized controlled trial?

34. Cancer-associated thrombosis: How many patients seen in clinical practice would be eligible for a direct oral anticoagulant randomized controlled trial?

35. Do all patients with cancer thrombosis have the same risk of bleeding and recurrence? Particularities of lung cancer.

36. Inhibition of Factor XI: A New Era in the Treatment of Venous Thromboembolism in Cancer Patients?

37. Effect of weight-adjusted intermediate-dose versus fixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism among noncritically and critically ill patients with COVID-19: the COVI-DOSE trial, a multicenter, randomised, open-label, phase 4 trial.

38. The hazard of combining anticoagulants with antiplatelets in patients with venous thromboembolism: Findings from the RIETE registry.

39. Pulmonary Embolism in the Cancer Associated Thrombosis Landscape.

40. Venous thromboembolism in patients with autoimmune disorders: a comparison between bleeding complications during anticoagulation and recurrences after its discontinuation.

41. Management of acute venous thromboembolism in patients taking antiplatelet therapy.

43. Long-term risk of postthrombotic syndrome after symptomatic distal deep vein thrombosis: The CACTUS-PTS study.

44. Monitoring of biological response to clopidogrel after treatment for non-cardioembolic ischemic stroke or transient ischemic attack.

45. Cancer incidence in patients with pre-capillary pulmonary hypertension.

46. Role of platelet α2-adrenoreceptor in biological low response to Clopidogrel for patients with non cardioembolic ischemic stroke or transient ischemic attack.

47. Screening cancer after venous thromboembolism: How many abnormal tests before diagnosing cancer? An analysis of practice.

48. Effect of Activated Charcoal on Rivaroxaban Complex Absorption.

49. Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial.

50. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial.

Catalog

Books, media, physical & digital resources